GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BrightPath Biotherapeutics Co Ltd (TSE:4594) » Definitions » Research & Development

BrightPath Biotherapeutics Co (TSE:4594) Research & Development : 円0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is BrightPath Biotherapeutics Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. BrightPath Biotherapeutics Co's Research & Development for the three months ended in Dec. 2023 was 円0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was 円0.00 Mil.


BrightPath Biotherapeutics Co Research & Development Historical Data

The historical data trend for BrightPath Biotherapeutics Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrightPath Biotherapeutics Co Research & Development Chart

BrightPath Biotherapeutics Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Research & Development
Get a 7-Day Free Trial Premium Member Only - - - - -

BrightPath Biotherapeutics Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BrightPath Biotherapeutics Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BrightPath Biotherapeutics Co  (TSE:4594) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


BrightPath Biotherapeutics Co Research & Development Related Terms

Thank you for viewing the detailed overview of BrightPath Biotherapeutics Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


BrightPath Biotherapeutics Co (TSE:4594) Business Description

Traded in Other Exchanges
N/A
Address
2-2-4 Kojimachi, Kojimachi Central Building 7th Floor, Chiyoda-ku, Tokyo, JPN
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.

BrightPath Biotherapeutics Co (TSE:4594) Headlines

No Headlines